ClinicalTrials.gg
CompletedNCT01513941INSIGHTUpdated May 5, 2016

An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)

A Phase 3 interventional study of Telaprevir and Ribavirin in Chronic Hepatitis C, sponsored by Janssen-Cilag International NV. Completed at 32 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-05-05.

Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
163
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing telaprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C, Chronic.

Enrollment
5th of 27
163 · median 54
Started
2012
with 8 others
Phase 3
12 of 27
none open now
Registered
17th of 27
by date
Lead sponsor
3 of 27
Janssen-Cilag International NV

Among the 27 studies testing telaprevir in Hepatitis C, Chronic, this one is the 5th largest by enrollment, is one of 9 that started in 2012, is one of 12 in phase 3, and was the 17th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 27 studies testing telaprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About telaprevir

telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies testing telaprevir in Hepatitis C, Chronic as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness and safety of telaprevir, given with pegylated-interferon-alfa-2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in the treatment of hepatitis C in patients infected with both chronic hepatitis C virus (HCV-1) and human immunodeficiency virus (HIV-1).

Read the detailed description

This is an open-label (both participant and investigator know the name of the medication given at a certain moment), single-arm, multicenter study in HCV treatment-naive and treatment-experienced patients infected with both chronic HCV-1 and HIV-1 to determine the efficacy and safety of telaprevir given with Peg-IFN-alfa-2a and RBV. The study will consist of 3 phases: a screening phase, an open-label treatment phase up to 48 weeks, and a follow-up period of 24 weeks. All patients will receive 12 weeks of treatment with telaprevir given with Peg-IFN-alfa-2a and RBV. At week 12 telaprevir dosing will end and patients will continue on Peg-IFN-alfa-2a and RBV. The total treatment duration in this study will be 24 or 48 weeks depending on the patient's prior HCV treatment status, liver disease status, and individual on-treatment virologic response in this study (equal response guided therapy). The maximum total duration of participation in the study for an individual participant will be approximately 76 weeks (screening included). Approximately 150 patients infected with both chronic HCV-1 and HIV-1 are planned to be enrolled.

03

Conditions studied

  • Chronic Hepatitis C

Keywords

  • Chronic hepatitis C
  • Genotype 1 chronic hepatitis C
  • Treatment experienced with HCV-1/HIV-1 coinfection
  • Telaprevir
  • Pegylated-Interferon-alfa-2a
  • Ribavirin
  • HCV-1/HIV-1 coinfection
  • Hepatitis C
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic (detectable Ribonucleic acid (RNA) more than 6 months prior screening or histological diagnosis based on liver or fibroscan) HCV infection genotype 1 with HCV RNA level greater than 1,000 IU/mL
  • Confirmed diagnosis of -1 infection greater than 6 months before the screening visit
  • greater than 300 cells/mm3 at screening and no value less than 200 cells/mm3 within 6 months of screening visit
  • HIV-1 RNA undetectable by an ultrasensitive assay at least once within 90 days of the screening visit
  • No HIV RNA values greater than 200 copies/mL within 6 months of the screening visit
  • Currently taking one of the permitted anti-HIV regimens for greater than or equal to12 weeks

Exclusion criteria

Exclusion Criteria:

  • Anticipated need to switch anti- regimen from screening through the Telaprevir treatment period
  • Infection or co-infection with other than genotype 1
  • to the administration of Peg-IFN-alfa or RBV
  • virus (HBV) co-infection
  • Acute or active condition of HIV-associated opportunistic infection within 6 months of screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
163 participants (actual)

Study arms

  • Experimental
    Telaprevir plus Pegylated-Interferon-alfa-2a /ribavirin (RBV)

    All patients who will receive 12 weeks of treatment with telaprevir 750 mg q8h except for patients on efavirenz will receive 1125 mg every 8 hours (q8h) in combination with Pegylated-Interferon-alfa-2a (Peg-IFN-alfa-2a) 180 μg/week and RBV 800 mg/day. At Week 12, telaprevir dosing will end and the patients will continue on Peg-IFN-alfa-2a and RBV.

    Drug: Telaprevir · Drug: Ribavirin · Drug: Pegylated-Interferon-alfa-2a

Interventions

  • Type=exact number, unit=mg, number=750 or 1125, form=tablet, route=oral. the patients will receive 2 oral tablets every 8 hours for 12 weeks except for patients on efavirenz who will receive 1125mg (3 oral tablets) every 8 hours for 12 weeks.

  • Type=exact number, unit=mg, number=400, form=tablet, route=oral. The patients will receive 2 oral ribavirin tablets twice daily for 24 or 48 weeks, based on the response guided therapy.

  • Type=exact number, unit=microgram, number=180, form=injection, route=subcutaneous The patients will receive Peg-IFN-alfa-2a 180 microgram once a week for 24 or 48 weeks; based on the response guided therapy.

06

What researchers measure

Primary outcomes

  1. Proportion of patients achieving undetectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels

    Proportion of patients achieving sustained virologic response (SVR) undetectable plasma HCV RNA levels 12 weeks after the last planned dose of study medication.

    Time frame: Up to 48 weeks

Secondary outcomes

  1. Change from baseline in log HCV RNA values

    Change from baseline in log HCV RNA values at each time point during treatment.

    Time frame: Baseline and week 48

  2. Proportiond of patients achieving undetectable HCV RNA levels

    Proportion of patients achieving SVR24 planned, defined as having undetectable plasma HCV RNA levels 24 weeks after the last planned dose of study medication.

    Time frame: Up to 48 weeks

  3. Proportion of patients achieving undetectable HCV RNA levels at Week 4

    The proportion of patients who achieve rapid virologic response (RVR) and undetectable HCV RNA levels at Week 4 of treatment.

    Time frame: Up to 48 weeks

  4. Proportion of patients achieving undetectable HCV RNA levels at Week 12

    Proportion of patients achieving undetectable HCV RNA levels at Week 12 of treatment.

    Time frame: Up to 48 weeks

  5. Proportion of patients achieving undetectable HCV RNA levels at Week 4 and Week 12 (eRVR)

    Proportion of patients achieving undetectable HCV RNA levels at Week 4 and Week 12 of treatment (eRVR).

    Time frame: Up to 48 weeks

  6. Proportion of patients achieving undetectable HCV RNA at the actual end of treatment

    Proportion of patients having undetectable HCV RNA levels at the actual end of treatment (ie, Week 24, Week 48, or early discontinuation).

    Time frame: Up to 48 weeks

  7. Proportion of patients achieving less than 25 IU/mL

    Proportion of patients having less than 25 IU/mL at the planned end of treatment (ie, Week 24 or Week 48).

    Time frame: Up to 48 weeks

  8. Proportion of patients with on-treatment virologic failure

    Proportion of patients with on-treatment virologic failure (an increase greater than 1 log in HCV RNA level from the lowest level reached, or a value of HCV RNA greater than 100 IU/mL in patients whose HCV RNA has previously become less than 25 IU/mL during treatment).

    Time frame: Up to 48 weeks

  9. Proportion of patients with relapse achieving detectable HCV RNA levels after previously undetectable HCV RNA levels

    Proportion of patients who relapse (having confirmed detectable HCV RNA during the follow-up period after previous undetectable HCV RNA levels (less than 25 IU/mL, undetectable) at planned end of treatment.

    Time frame: Up to 48 weeks

  10. Proportion of patients with relapse achieving detectable HCV RNA levels after previous HCV RNA levels

    Proportion of patients who relapse, defined as having confirmed detectable HCV RNA during the follow-up period after previous HCV RNA less than 25 IU/mL at planned end of treatment.

    Time frame: Up to 48 weeks

07

Study locations

32 sites
  • Cairns, Australia
  • Darlinghurst, Australia
  • Melbourne, Australia
  • Campinas, Brazil
  • Rio De Janeiro, Brazil
  • Santo André, Brazil
  • Sao Paulo, Brazil
  • Le Kremlin Bicetre, France
  • Marseille, France
  • Nice N/A, France
  • Paris Cedex 12, France
  • Bydgoszcz, Poland
  • Myslowice, Poland
  • Warszawa, Poland
  • Krasnodar, Russian Federation
  • Perm, Russian Federation
  • Saint-Petersburg, Russian Federation
  • Smolensk, Russian Federation
  • St Petersburg, Russian Federation
  • Voronezh, Russian Federation
  • Alicante, Spain
  • Badalona, Spain
  • Cordoba, Spain
  • Elche, Spain
  • Madrid, Spain
  • San Sebastian, Spain
  • Sevilla N/A, Spain
  • Valencia, Spain
  • Stockholm, Sweden
  • Birmingham, United Kingdom
  • Glasgow, United Kingdom
  • London, United Kingdom
08

References and documents

Publications

  • Montes ML, Nelson M, Girard PM, Sasadeusz J, Horban A, Grinsztejn B, Zakharova N, Rivero A, Durant J, Ortega-Gonzalez E, Lathouwers E, Janssen K, Ouwerkerk-Mahadevan S, Witek J, Gonzalez-Garcia J. Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study. J Antimicrob Chemother. 2016 Jan;71(1):244-50. doi: 10.1093/jac/dkv323. Epub 2015 Oct 19. PubMed 26483516 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Mar 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2012
First posted
Jan 20, 2012
Start
Apr 2012
Primary completionActual
Mar 2014
CompletionActual
Jun 2014
Last update
May 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01513941
Responsible party
Sponsor
First posted
Jan 20, 2012
Start date
Apr 2012
Primary completion
Mar 2014
Completion
Jun 2014
Last update
May 5, 2016

Study contacts

Janssen-Cilag International NV, Belgium Clinical Trial
study director · Janssen-Cilag International NV

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telaprevir · Ribavirin · Peginterferon alfa-2a

Start the discussion